The global prothrombin complex concentrate (PCC) size is poised to reach USD 1,076.5 million by 2025, registering a CAGR of 9.1% during the forecast period. Rising prevalence of hemophilia across the globe is expected to be a major growth driver for this market. Hemophilia is a rare blood disorder wherein normal blood clotting does not occur due to absence or insufficient amount of clotting proteins in the individual’s blood. Though rare, the disorder has been found to have increased in prevalence. According to a study led by Canada’s McMaster University, more than 1,125,000 men worldwide suffer from this inherited affliction. PCC treatments have been found to be highly effective in managing hemophilia, a study published in JAMA Pediatrics, a peer-reviewed medical journal, found. This bodes well for the prothrombin complex concentrate market growth as adoption rate of PCC therapeutics picks up pace.
For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/prothrombin-complex-concentrate-pcc-market-100102
Fortune Business Insights identifies the following players in the PCC market:
- China Biologic Products Holdings, Inc.
- Grifols SA
- Octapharma AG
- Kedrion S.p.A
- CSL Behring
Asia-Pacific to Boast a High CAGR; North America to Dominate
With a revenue generation of USD 210.2 million in 2017, North America is set to lead the global prothrombin complex concentrates market share in the forecast period. This is mainly owing to the presence of major players in the region. Evolving health insurance policies for rare blood disorders and increase in the number of plasma collection centres in India and China will enable Asia-Pacific to grow at an impressive CAGR till 2025. In Europe, the market will be driven by the rising prevalence of congenital coagulation factors deficiency.
Request a Sample Copy of Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/prothrombin-complex-concentrate-pcc-market-100102
Growing Utilization of 4-Factor PCC to Boost Sales
The 4-factor prothrombin complex concentrate (4F-PCC) is used to expedite the reversal of vitamin K antagonist (VKA). It carries several benefits which is fuelling its popularity. For example, this PCC variant contains coagulation factor VII, which is not present in other variants. Furthermore, administering 4F-PCC is relatively easy as it requires a reduced infusion volume and it also minimizes the risk of pathogen transmission. Effectivity of its treatment mechanism has surged its adoption rate and given it international recognition. For instance, the British Committee for Standards in Haematology has prescribed specific guidelines for the deployment of PCC techniques in treating haemophiliacs. These developments are expected to provide a positive thrust to the market for this medication technology.
Operational Diversification by Players to Intensify Competition
According to the prothrombin complex concentrate market trends, key players are adopting strategies to expand, disperse, and diversify their operational reach with a view to strengthen their position in the PCC market. This is being accomplished through partnerships with other companies and acquisition activities.
Key industry developments:
- June 2017: The Chinese plasma fractionator, Wuhan Zhong Yuan Rui De Biological, was acquired by CSL Behring to establish CSL’s presence in the plasma fractionation market in China. This move was further vindicated when CSL’s PCC brand, Kcentra, got cleared for commercial release in Japan.
- August 2018: Grifols S.A. took over 24 plasma donation centres in the US, thereby strengthening its supply of plasma proteins for blood disorder treatments.
More Trending Topics from Fortune Business Insights: